Danielle E Otto
Overview
Explore the profile of Danielle E Otto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butts A, Ellis C, Travers E, Reynolds J, Rogers L, Otto D, et al.
J Oncol Pharm Pract
. 2023 Jul;
:10781552231185527.
PMID: 37431207
Objective: Patients receiving infusions for the treatment of cancer are commonly prescribed supportive care medications which are filled through retail pharmacies. The initial phase of the COVID-19 pandemic created hurdles...
2.
Myint Z, St Clair W, Strup S, Yan D, Li N, Allison D, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173971
Purpose: Cannabinoids (CBD) have anti-tumor activity against prostate cancer (PCa). Preclinical studies have demonstrated a significant decrease in prostate specific antigen (PSA) protein expression and reduced tumor growth in xenografts...
3.
Myint Z, Kolesar J, McCorkle J, Wu J, Ellis C, Otto D, et al.
Med Sci Monit
. 2022 Oct;
28:e938091.
PMID: 36229939
BACKGROUND Prostate cancer growth is primarily driven by testosterone and 5a-dihydrotestosterone. Abiraterone is an irreversible inhibitor of CYP17, and CYP17 inhibition is a required step in testosterone biosynthesis. Previous studies...
4.
Myint Z, Momo H, Otto D, Yan D, Wang P, Kolesar J
JAMA Netw Open
. 2020 Nov;
3(11):e2025826.
PMID: 33201234
Importance: A high incidence of fall and fracture in a subset of patients treated with androgen receptor inhibitors (ARIs) has been reported, although the relative risk (RR) of fall and...